HH 3806
Alternative Names: HH-3806Latest Information Update: 19 Dec 2023
At a glance
- Originator HaiHe Biopharma
- Class Antineoplastics
- Mechanism of Action BRD2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in Australia (unspecified route) (HaiHe Biopharma pipeline, December 2023).
- 18 Nov 2022 Preclinical trials in Solid tumours in China (unspecified route) as of November 2022 (HaiHe Biopharma pipeline, November 2022)
- 06 Oct 2020 HH 3806 is available for licensing as of 06 Oct 2020. http://en.haihepharma.com/haihe_en/bk_18821334.html